
Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.
This Urology Times supplement was produced by Advanstar Medical Education Services under an unrestricted grant from Laserscope www.laserscope.com. The views and opinions in this supplement are those of the interviewed physicians and do not necessarily reflect the views of the editors, Advanstar Medical Education Services or Laserscope.Copyright 2002 Advanstar Communications Inc. All rights reserved.






